

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

39. (currently amended) An isolated polypeptide of less than 60 amino acid residues comprising the at least one amino acid sequence BX7B (SEQ ID NO: 28) which binds hyaluronic acid, HA wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 69 and SEQ ID NO: 71.

40. (currently amended) A composition comprising the polypeptide at least one polypeptide according to of Claim 39.

41. (new) The polypeptide of claim 39 which is less than 50 amino acid residues.

42. (new) The polypeptide of claim 39 which is less than 40 amino acid residues.

43. (new) The polypeptide of claim 39 which is less than 30 amino acid residues.

44. (new) The polypeptide of claim 39 which is less than 20 amino acid residues.

45. (new) The polypeptide of claim 39 which is an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 69 and SEQ ID NO: 71.

46. (new) The composition of claim 40 which comprises a pharmaceutically or physiologically acceptable carrier, excipient or diluent.

47. (new) The composition of claim 40 which is adapted for administration by a route selected from the group consisting of systemic, oral, rectal, intravenous, intramuscular, subcutaneous, ocular and topical.

48. (new) The composition of claim 40 wherein the polypeptide is delivered at a dose ranging from 1 ng/kg to 80 mg/kg.

49. (new) A method of treating a condition selected from the group consisting of tissue disorders associated with a response-to-injury process, proliferative disorders and diseases and inflammatory disorders and diseases comprising administering to a subject in need thereof at least one polypeptide according to any of claims 39 or 41-45.

50. (new) A method of treating a condition selected from the group consisting of tissue disorders associated with a response-to-injury process, proliferative disorders and diseases and inflammatory disorders and diseases comprising administering to a subject in need thereof at least one composition according to any of claims 40 or 46-48.

51. (new) The method of claim 49 wherein the condition is selected from the group consisting of multiple sclerosis, diabetes, obesity, wounds and restenosis.

52. (new) The method of claim 50 wherein the condition is selected from the group consisting of multiple sclerosis, diabetes, obesity, wounds and restenosis.